Investigating the link between cardiovascular disease and non-alcoholic fatty liver disease.
A Cardiovascular-NASH disease nexus: Common Mechanisms and Treatments?
['FUNDING_P01'] · UNIVERSITY OF CALIFORNIA, SAN DIEGO · NIH-10908526
This study is looking at how non-alcoholic fatty liver disease might increase the chances of heart problems, and it’s exploring new treatments that could help lower that risk for people with this condition.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN DIEGO (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-10908526 on ClinicalTrials.gov |
What this research studies
This research explores how non-alcoholic fatty liver disease (NAFLD) contributes to the risk of cardiovascular disease (CVD). It examines the role of liver fat and fibrosis in predicting CVD risk and investigates potential treatments targeting specific receptors in the liver and gut. By using small molecules and antibodies, the study aims to uncover common mechanisms that connect these two diseases. Patients may benefit from insights that could lead to new therapies aimed at reducing their risk of cardiovascular complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-alcoholic fatty liver disease, particularly those at risk for cardiovascular complications.
Not a fit: Patients without any form of liver disease or those who do not have cardiovascular risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that reduce the risk of cardiovascular disease in patients with fatty liver disease.
How similar studies have performed: Previous research has shown promising results in understanding the connections between liver disease and cardiovascular health, suggesting that this approach could yield significant insights.
Where this research is happening
LA JOLLA, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN DIEGO — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GLASS, CHRISTOPHER K — UNIVERSITY OF CALIFORNIA, SAN DIEGO
- Study coordinator: GLASS, CHRISTOPHER K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Atherosclerotic Cardiovascular Disease